Pharma Journalist -

Roche announced that the Phase III IMpassion031 study, evaluating Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel; followed…
Read More...

Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA),…
Read More...

Orca Bio, a clinical-stage biotechnology company developing high precision allogeneic cell therapies, announced a Series D financing that brings its total capital raised since its 2016…
Read More...

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at…
Read More...

ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo…
Read More...

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and…
Read More...

PDS Biotechnology Corporation announced a co-development agreement with Farmacore Biotechnology for Versamune-CoV-2FC, a Versamune-based vaccine aimed at preventing COVID-19 infection.…
Read More...

Jazz Pharmaceuticals plc announced along with its partner PharmaMar that the U.S. Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for the treatment of adult…
Read More...

Merck, known as MSD outside the United States and Canada, and Pfizer Inc. announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that…
Read More...